TuHURA Biosciences, Inc./NV (HURA) - Dilution Analysis

10-Q filing | 60.0M shares outstanding

10-Q filing | 50.7M shares outstanding

S-3 filing: TuHURA Biosciences, Inc. may offer and sell from time to time up to $250,000,000 of any combination of debt securities, common stock, preferred stock, subscription rights, and purchase contracts, in one or more classes or series and in amounts, at prices and on terms that they will determine at the times of the offerings; additionally, the selling stockholders may offer and sell from time to time up to 9,321,545 shares of our Common Stock, comprising up to (i) 4,570,629 shares of our Common Stock and (ii) 4,750,916 shares of our Common Stock issuable upon the exercise of warrants under this prospectus.

S-1/A filing: This S-1/A filing relates to the resale of common stock and common stock issuable upon the exercise of warrants by selling stockholders.

10-Q filing | 50.0M shares outstanding

S-1 filing: This S-1 filing describes the resale of up to 9,518,618 shares of the company's common stock by selling stockholders, comprising 4,759,309 shares of common stock and 4,759,309 shares of common stock issuable upon the exercise of warrants.

10-Q filing | 43.4M shares outstanding

10-K filing | 43.7M shares outstanding

10-Q filing | 42284.5M shares outstanding

8-K filing: Kintara announced a reverse stock split of its common stock at a ratio of 1-for-35 immediately prior to the consummation of the proposed Merger and will issue CVRs to stockholders of record immediately prior to the reverse stock split, entitling the holders to an aggregate of 53,897,125 shares of Kintara's common stock, which number is subject to adjustment as a result of Kintara's proposed reverse stock split.

10-K filing | 55660.6M shares outstanding

10-Q filing | 55304.6M shares outstanding

RW filing: Kintara Therapeutics, Inc. has requested the withdrawal of its Registration Statement on Form S-1 (File No. 333-274864) as it does not intend to pursue the contemplated public offering of the securities covered by the Registration Statement at this time.

10-Q filing | 39037.9M shares outstanding

10-Q filing | 3387.8M shares outstanding

S-1/A filing: This is an S-1/A filing for an offering of common stock, pre-funded warrants, and common warrants, with A.G.P./Alliance Global Partners as the placement agent.

S-1/A filing: This S-1/A filing by Kintara Therapeutics, Inc. relates to a proposed offering of common stock, pre-funded warrants, and common warrants with a total proposed amount of $10,000,000, intended for working capital and general corporate purposes.

S-1 filing: The filing is an S-1 for an offering of common stock, pre-funded warrants, and common warrants. The common stock is listed on the Nasdaq Capital Market under the symbol KTRA.

8-K filing: Kintara Therapeutics, Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners to offer and sell shares of its common stock having an aggregate offering price of up to $2.85 million. ($2.85M proceeds)

10-K filing | 1.6M shares outstanding

10-Q filing | 1.7M shares outstanding

10-Q filing | 1.6M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 73,205,000 → 1,464,100

10-Q filing | 73.2M shares outstanding

10-K filing | 80.8M shares outstanding

8-K filing: Kintara Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $20.0 million of shares of the Company's common stock, and issued 1,630,191 shares of Common Stock to Lincoln Park as a commitment fee.

10-Q filing | 65.5M shares outstanding

8-K filing: Kintara Therapeutics, Inc. entered into a Securities Purchase Agreement to issue and sell 16,226,416 shares of common stock and investor warrants to purchase up to 16,226,416 shares in a registered direct offering, with gross proceeds of approximately $8.6 million. ($8.6M proceeds)

10-Q filing | 48.5M shares outstanding

10-Q filing | 48.5M shares outstanding

8-K filing: Kintara Therapeutics, Inc. entered into a Securities Purchase Agreement to issue and sell 7,200,000 shares of common stock, pre-funded warrants to purchase 4,800,000 shares, and investor warrants to purchase 12,000,000 shares in a registered direct offering, with gross proceeds of $15.0 million. ($15.0M proceeds)

10-K filing | 43.2M shares outstanding

10-Q filing | 32.6M shares outstanding

S-3 filing: Kintara Therapeutics, Inc. files an S-3 form to register securities for potential sale, with an aggregate offering price not to exceed $100,000,000, including common stock, preferred stock, warrants, debt securities, subscription rights and units.

10-Q filing | 30.6M shares outstanding

10-Q filing | 24.7M shares outstanding

S-3 filing: The selling stockholders may offer from time to time up to 34,990,252 shares of our common stock.

10-K filing | 23.5M shares outstanding

8-K filing: The Company completed the final closing of a private placement of Series C-3 Preferred Stock, selling 3,256 shares at $1,000 per share, and also issued Placement Agent Warrants to purchase shares of Series C-1, C-2, and C-3 Preferred Stock. ($3.26M proceeds)

8-K filing: The company completed a private placement involving the sale of Series C-2 Preferred Stock and entered into agreements for registration rights and placement agency services, and the Certificate of Designation includes adjustments for stock splits and stock dividends. ($2.19M proceeds)

8-K filing: Kintara Therapeutics, Inc. executed a private placement involving the sale of Series C-1 Preferred Stock and issued common stock to Aegis Capital Corp. as compensation for advisory services. ($19.59M proceeds)

10-Q filing | 11.4M shares outstanding

10-Q filing | 11.4M shares outstanding